Monkeypox Outbreak Global Threat and Lessons from a Reemerging Virus

Introduction

As the world continues recovering from COVID-19, a new viral threat loomsmonkeypox, a zoonotic disease previously limited to West and Central Africa. Its reemergence in non-endemic regions raises global public health concerns. The International Journal of Clinical Virology recently published a review by Dr. Sukhvir Kaur exploring the origin, symptoms, transmission, and vaccination updates surrounding the monkeypox virus.
Visit https://www.clinvirologyjournal.com/ for more groundbreaking research in virology and infectious diseases.

Understanding Monkeypox: Origins and Epidemiology

• First identified in monkeys in Denmark in 1958 and later in a human in the Democratic Republic of Congo in 1970.
• Reemerged globally in 2022 with over 48,000 reported cases, including non-endemic countries like the US, UK, and Singapore.
• Genetically, it belongs to the Orthopoxvirus genus and is related to the smallpox virus.

Transmission and Symptoms

• Transmission Routes:
  • Close contact with body fluids, skin lesions, and respiratory droplets.
  • Contact with contaminated clothing or surfaces.
  • Possible vertical transmission (mother to fetus).
• Symptoms:
  • Fever, rash (including palms and soles), muscle aches, fatigue.
  • Lesions typically begin in the oropharynx and spread across the body.
  • Incubation period: 6–13 days; contagious during the rash phase.

Complications and Mortality Risks

• Can lead to severe complications including:
  • Encephalitis
  • Sight-threatening keratitis
  • Sepsis
  • Dehydration
  • Skin scarring and death
• Mortality rates reported between 1% to 10%, higher among children and immunocompromised individuals.

Diagnosis and Detection Methods

• Gold Standard: PCR testing from skin lesion samples.
• Biopsies are an option but less common.
• Serology and antigen tests are not specific and not recommended.
• Full study at https://doi.org/10.29328/journal.ijcv.1001048

Current Treatment Strategies

Although no licensed treatment is currently available, the following approaches are used:

• Supportive care remains the primary mode.
• Antiviral drugs like Brincidofovir and Tecovirimat show promise.
• CDC suggests smallpox vaccination within 4 days post-exposure can prevent infection.

Vaccines Available for Prevention

Several vaccines are now being considered or approved for emergency use:

• JYNNEOS: Two-dose smallpox vaccine offering ~85% protection.
• ACAM2000: Single dose, older generation vaccine.
• MVA-BN and LC16: Newer, safer smallpox vaccines suitable for broader populations.

The American Society for Microbiology (ASM) also stresses early diagnosis and vaccination for prevention. The CDC’s guidance provides updated recommendations for clinicians and the public.

Global Outlook and Importance of Awareness

The spread of monkeypox beyond traditional endemic zones reveals global vulnerability. Strengthening surveillance, early diagnosis, and preventive strategies is crucial to prevent another pandemic-scale crisis.
A detailed analysis can be found in our main journal article. For more insights, explore related studies on https://www.clinvirologyjournal.com/.

Call to Action

Explore more studies at https://www.clinvirologyjournal.com/ and join the conversation by sharing your thoughts in the comments below!

Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference. Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.